Company news

Amneal Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals

June 14, 2023

Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable

June 13, 2023

Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States

May 15, 2023

Amneal Reports First Quarter 2023 Financial Results

May 4, 2023

Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance

April 16, 2023

Amneal to Report First Quarter 2023 Results on May 5, 2023

April 11, 2023

Amneal Reports Fourth Quarter and Full Year 2022 Financial Results

March 1, 2023

Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

March 1, 2023

Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023

January 30, 2023

Amneal Announces Strategic European Partnership with Orion Corporation

January 3, 2023

Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

December 19, 2022

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

November 21, 2022

Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

November 10, 2022

Amneal Reports Third Quarter 2022 Financial Results

November 3, 2022

Amneal Receives FDA Approval for Leuprolide Acetate Injection

November 1, 2022

Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory

October 30, 2022

Amneal to Report Third Quarter 2022 Results on November 4, 2022

October 5, 2022

Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States

October 2, 2022

Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty

September 5, 2022

Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

August 30, 2022

Amneal supports Congress’ efforts to ensure essential medicines are Made in America

August 21, 2022

Amneal launches 4 new Generic products, including Vasopressin single-dose

August 10, 2022

Amneal Reports Second Quarter 2022 Financial Results

August 4, 2022

Amneal Appoints Deborah M. Autor to Board of Directors

August 2, 2022

Amneal to Report Second Quarter 2022 Results on August 5, 2022

July 7, 2022

Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration

June 6, 2022

Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders

May 31, 2022

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)

May 26, 2022

Amneal Reports First Quarter 2022 Financial Results

May 3, 2022

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)

April 12, 2022

Amneal to Report First Quarter 2022 Results on May 4, 2022

April 6, 2022

Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting

March 23, 2022

Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries

March 16, 2022

Amneal Reports Fourth Quarter and Full Year 2021 Financial Results

March 1, 2022

Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)

February 28, 2022

Amneal Expands Injectables Portfolio with 4 New Products

February 16, 2022

Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022

February 3, 2022

Amneal Acquires Saol Therapeutics’ Baclofen Franchise

January 4, 2022

Amneal Receives Approval for Difluprednate Ophthalmic Emulsion

November 18, 2021

Amneal Reports Third Quarter 2021 Financial Results

November 2, 2021

Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company

November 1, 2021

Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA

October 26, 2021

Amneal to Report Third Quarter 2021 Results on November 3, 2021

October 5, 2021

Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

August 24, 2021

Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

August 22, 2021

Amneal Reports Second Quarter 2021 Financial Results

August 8, 2021

Amneal Receives Approval for Generic TobraDex®

July 18, 2021

Amneal to Report Second Quarter 2021 Results on August 9, 2021

July 14, 2021

Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab

June 16, 2021

Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches

June 6, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.